Michael Mortensen

Chief Operating Officer at BONESUPPORT HOLDING AB

Net worth: 677 291 $ as of 31/05/2024

49 year

Consumer Services

Health Technology

Profile

Michael Wrang Mortensen is currently the Director of Development & Supply at Nanovi Radiotherapy A and the EVP of Research, Development & Operations at BONESUPPORT HOLDING AB.
He has a graduate degree from the Technical University of Denmark, a doctorate degree from the University of Copenhagen, and an MBA from AVT Business School A.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
BONESUPPORT HOLDING AB 0.04%	27/05/2024	28,000 ( 0.04% )	677 291 $	31/05/2024

Michael Mortensen active positions

Companies	Position	Start
BONESUPPORT HOLDING AB	Chief Operating Officer	01/12/2021
Nanovi Radiotherapy A/S Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark.	Corporate Officer/Principal	-

All active positions of Michael Mortensen

Training of Michael Mortensen

University of Copenhagen	Doctorate Degree
Technical University of Denmark	Graduate Degree
AVT Business School A/S	Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Michael Mortensen's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
BONESUPPORT HOLDING AB	Health Technology

Private companies	1
Nanovi Radiotherapy A/S Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark.	Health Technology